发明名称 |
TREATMENT OF LEUKEMIAS AND CHRONIC MYELOPROLIFERATIVE DISEASES WITH ANTIBODIES TO EPHA3 |
摘要 |
Patent No. 594950 Disclosed is the use of an anti-EphA3 antibody in the manufacture of a medicament for treating a myeloproliferative disorder in a patient, wherein the patient has myeloproliferative disorder cells that express EphA3 on the cell surface and wherein the anti-EphA3 antibody (i) activates EphA3 and (ii) induces ADCC. Also disclosed is a method of monitoring the efficacy of treatment of a patient having a myeloproliferative disorder with EphA3+ myeloproliferative cells, wherein the myeloproliferative disorder is AML or MDS, the method comprising: providing a sample previously obtained from the patient comprising myeloproliferative disorder stem cells and/or blast cells from the patient following a therapeutic treatment for the myeloproliferative disorder; and detecting expression of EphA3 on the myeloproliferative disorder stem cells and/or blast cells. |
申请公布号 |
NZ594950(A) |
申请公布日期 |
2013.06.28 |
申请号 |
NZ20100594950 |
申请日期 |
2010.03.05 |
申请人 |
KALOBIOS PHARMACEUTICALS, INC. |
发明人 |
BEBBINGTON, CHRISTOPHER, R |
分类号 |
C07K16/28;A61K39/00;A61K39/395 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|